LUNG CANCER, 4TH EDITION

Contributors, viii
Preface, xiii
1 Smoking Prevention and Cessation, 1
2 Lung Cancer Susceptibility and Risk Assessment Models, 25
3 Molecular Profiling, 48
4 Somatic Genome Alterations in Human Lung Cancers, 67
5 Serum Proteomic Biomarkers, 90
6 Molecular Biology of Lung Preneoplasia, 110
7 Detection and Treatment of Preneoplastic Lesions, 129
8 Pathology of Adenocarcinoma, 144
9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158
10 Radiology and Lung Cancer Screening, 176
11 Imaging Lung Cancer, 191
12 Staging of the Mediastinum, 202
13 Management of the Solitary Pulmonary Nodule, 214
14 Minimally Invasive Resections for Lung Cancer, 224
15 Extended Resections for Lung Cancer, 236
16 Bronchoscopic Interventions for Lung Cancer, 253
17 Primary Tracheal Tumors, 267
18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278
19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290
20 Image-Guided Radiation Therapy, 309
21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320
22 Proton Therapy, 338
23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353
24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379
25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390
26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406
27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421
28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435
29 Immunologic Approaches to Lung Cancer Therapy, 454
30 Novel and Emerging Agents in NSCLC, 464
31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479
32 Novel Statistical Models for NSCLC Clinical Trials, 488
33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505
34 Anti-angiogenic Agents in Metastatic NSCLC, 527
35 Targeting ALK Rearrangements, 541
36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557
37 Prognostic and Predictive Biomarker Signatures, 564
38 Brain Metastasis from Lung Cancer, 572
Index, 591

The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease.
Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded Lung Cancer is better than ever –featuring nine new chapters along with seven re-formatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; and more.

This Fourth Edition of Lung Cancer:
• Provides the very latest research in the identification of biomarkers to predict a high risk for developing lung cancer – vital for implementing screening, diagnosis, and prevention strategies
• Presents the newest lung cancer staging system, as well as updated and cutting-edge surgical and radiation therapy techniques that make local tumor control more effective and less invasive while sparing normal tissues
• Discusses combined modality therapy and new chemotherapeutic agents which are yielding higher response rates and improved survival when used in the adjuvant setting or concurrent with highly sophisticated radiation or proton treatment
• Offers novel and emergent approaches to preventative, diagnostic, and therapeutic modalities with an emphasis on the best evidence available from the latest studies and clinical trials

With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.

Author Information
• Jack A. Roth, MD, F.A.C.S., is Professor and Bud Johnson Clinical Distinguished Chair in the Department of Thoracic and Cardiovascular Surgery, Professor of Molecular and Cellular Oncology, Director of the W.M. Keck Center of Innovative Cancer Therapies, and Chief of the Section of Thoracic Molecular Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
• James D. Cox, MD, is Professor and Head of the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
• Waun Ki Hong, MD, D.M.Sc. (Hon.), is the American Cancer Society Professor and Samsung Distinguished University Chair in Cancer Medicine, as well as Professor and Head of the Division of Cancer Medicine and Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.